Mayne Pharma Group (MAYNF) Stock Price, News & Analysis

Company Overview

Mayne Pharma Group (OTCMKTS:MAYNF) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of prescription products. The company’s portfolio spans oral, transdermal and topical dosage forms, with a particular emphasis on women’s health, dermatology, pain management and other niche therapeutic areas. Through both branded and generic offerings, Mayne Pharma seeks to address unmet patient needs and provide cost-effective alternatives to established treatments.

In its development operations, Mayne Pharma leverages a combination of in-house research and external partnerships to advance product candidates through regulatory review. The company operates multiple manufacturing sites across Australia, the United States and the United Kingdom, enabling end-to-end production from active pharmaceutical ingredient (API) synthesis to finished-dose packaging. This integrated model supports tight quality controls and flexible scale-up for both its own products and those made under contract for third-party clients.

Mayne Pharma’s contract development and manufacturing organization (CDMO) provides development services, commercial manufacturing and packaging solutions to global pharmaceutical and biotechnology companies. By offering a range of formulation technologies—such as film-coating, transdermal adhesives and semi-solid topical systems—the company addresses complex product requirements and accelerates time to market for partners.

Since its spin-off from a larger Australian healthcare group in the early 2000s, Mayne Pharma has grown through a combination of organic investment and strategic acquisitions, expanding its presence in key markets. Headquartered in Melbourne with a significant commercial office in Raleigh, North Carolina, the company is led by Chief Executive Officer Scott Richards. Mayne Pharma continues to pursue a balanced strategy of strengthening its specialty pharmaceutical pipeline while supporting external clients through its CDMO capabilities.

Key Stats

• Today's Range: $3.69 to $3.69
• 50-Day Range: $2.82 to $3.76
• 52-Week Range: $2.42 to $4.60
• Volume: 1,750 shs
• Average Volume: 1,789 shs
• Market Capitalization: N/A
• P/E Ratio: 102.50
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mayne Pharma Group Stock Analysis - MarketRank™

Mayne Pharma Group scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mayne Pharma Group.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mayne Pharma Group is 102.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 231.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mayne Pharma Group is 102.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 85.31.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Mayne Pharma Group has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mayne Pharma Group has recently increased by 22.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mayne Pharma Group does not currently pay a dividend.

Dividend Growth

Mayne Pharma Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Mayne Pharma Group has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mayne Pharma Group has recently increased by 22.22%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: N/A

News Sentiment

Mayne Pharma Group has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mayne Pharma Group insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 15.80% of the stock of Mayne Pharma Group is held by institutions.

MAYNF Stock Analysis - Frequently Asked Questions

How have MAYNF shares performed this year?

Mayne Pharma Group's stock was trading at $2.79 at the beginning of 2025. Since then, MAYNF stock has increased by 32.3% and is now trading at $3.69.

When did Mayne Pharma Group's stock split?

Mayne Pharma Group's stock reverse split on the morning of Wednesday, January 18th 2023.The 1-20 reverse split was announced on Wednesday, January 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Mayne Pharma Group?

Shares of MAYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MAYNF
• CIK: N/A
• Web: www.maynepharma.com
• Phone: (188) 209-2666
• Fax: N/A
• Employees: 780
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 102.50
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A